EMA accepts filing for Biogen/Samsung Bioepis’ Lucentis biosimilar
Biosimilar is an anti-VEGF therapy for retinal vascular disorders
7th October 2020
Latest news
Systematic benefit-risk study deems remdesivir a ‘favourable’ COVID-19 treatment
Study recorded all possible benefits and risks for COVID-19 patients receiving treatment
7th October 2020
Merck KGaA out-licenses osteoarthritis programme to Novartis
Potential disease modifying osteoarthritis candidate is phase II ready
7th October 2020
UK inks deal with Abingdon Health for rapid COVID-19 antibody tests
Government has placed first order for one million tests
7th October 2020
New drug shows potential for treating childhood neuroblastoma
Drug is ready to progress into clinical trials after passing initial safety test
6th October 2020
Uni of Manchester partners with AVROBIO for Hunter syndrome gene therapy
Investigational gene therapy was developed by professor Brian Bigger
6th October 2020
Oncimmune/Medicines Discovery Catapult win UK government funding for COVID-19 research tool
Research tool will predict disease severity and therapeutic response
6th October 2020
ViiV’s two-drug HIV regimen demonstrates long-term efficacy
Two-drug regimen continues to offer non-inferior efficacy compared to a three-drug regimen
6th October 2020
Janssen/MeiraGTx showcase nine-month data for sight loss gene therapy
Gene therapy demonstrated improvement in retinal sensitivity
5th October 2020
BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma
Combination treatment did not achieve statistical significance in all-comer population
5th October 2020
Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population
New approval includes older adolescents and adults with rare disease
5th October 2020
NHS commits to becoming ‘carbon net zero’ by 2040
NHS is aiming to become world's first carbon net zero national health system
5th October 2020
NHS England report identifies need for ‘radical change’ in diagnostic services
Diagnostics: Recovery and Renewal report identifies a number of key actions
2nd October 2020
Pfizer scores a speedy review in the US for Duchenne gene therapy
Fast track designation is based on promising phase Ib results
2nd October 2020
AZ’s COVID-19 vaccine trial resumes in Japan
US Food and Drug Administration broadens investigation into serious adverse event
2nd October 2020
